Online inquiry

IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11869MR)

This product GTTS-WQ11869MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets GUCY2C gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_004963.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2984
UniProt ID P25092
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11869MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10790MR IVTScrip™ mRNA-Anti-G, M777-16-3(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA M777-16-3
GTTS-WQ2102MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA Alb-IFNA2 R23 (608)
GTTS-WQ16001MR IVTScrip™ mRNA-Anti-ERBB2, ZW-25(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ZW-25
GTTS-WQ15809MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA XmAb14045
GTTS-WQ4482MR IVTScrip™ mRNA-Anti-CD28, BMS-931699(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BMS-931699
GTTS-WQ925MR IVTScrip™ mRNA-Anti-EGFR, ABBV-321(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-321
GTTS-WQ13603MR IVTScrip™ mRNA-Anti-APP, R1450(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA R1450
GTTS-WQ1863MR IVTScrip™ mRNA-Anti-CTLA4, AGEN1884(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AGEN1884
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW